• Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Lauruslabs Share Price

    Laurus Labs Share PriceLaurus Labs

    Large Cap 11k Result
    ₹380.95
    6.15 (1.64%)
    • Advice
    • Hold
    As on 30 November, 2023 | 11:23 BSE: 540222 NSE: LAURUSLABSISIN: INE947Q01028
    Split

    Laurus Labs Performance

    Day Range

    • Low 374.30
    • High 381.00
    ₹ 380.95

    52 Week Range

    • Low 278.85
    • High 443.90
    ₹ 380.95
    • Open Price375.50
    • Previous Close374.80
    • Volume643072

    Start SIP in Laurus Labs

    Start SIP

    Laurus Labs Share Price

    • Over 1 Month 6.77%
    • Over 3 Month -2.58%
    • Over 6 Month 13.84%
    • Over 1 Year -6.77%

    Laurus Labs Key Statistics

    P/E Ratio 55.8
    PEG Ratio -1
    Market Cap Cr 20,520
    Price to Book Ratio 5.1
    EPS 14.1
    Dividend 0.4
    Relative Strength Index 51.11
    Money Flow Index 69.35
    MACD Signal -2.99
    Average True Range 8.53

    Laurus Labs F&O

    Laurus Labs Futures
    Laurus Labs Option Chain

    Laurus Labs Investment Rating

    • Master Rating:

    • Laurus Labs has an operating revenue of Rs. 5,331.96 Cr. on a trailing 12-month basis. An annual revenue growth of 22% is outstanding, Pre-tax margin of 18% is great, ROE of 19% is exceptional. The company has a reasonable debt to equity of 19%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 6% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 10% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 47 which is a POOR score indicating inconsistency in earnings, a RS Rating of 26 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 79 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Laurus Labs Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 1,1581,1081,2791,5011,4981,4951,378
    Operating Expenses Qtr Cr 9789801,0271,1161,0721,0771,005
    Operating Profit Qtr Cr 181128252385426418373
    Depreciation Qtr Cr 85848178766661
    Interest Qtr Cr 38334139382829
    Tax Qtr Cr 1743571899664
    Net Profit Qtr Cr 4713102199227232221
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 5,7894,721
    Operating Expenses Annual Cr 4,2923,422
    Operating Profit Annual in Cr 1,4821,285
    Depreciation Cr 301235
    Interest Annual Cr 14688
    Tax Annual Cr 291225
    Net Profit Annual Cr 760750
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 882823
    Cash from Investing Activity Annual Cr -735-837
    Cash from Financing Annual Activity Cr -18515
    Net Cash Flow Annual Cr -392
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 4,0573,388
    Fixed Assets Annual Cr 3,2412,941
    Total Non Current Assets Annual Cr 3,7873,404
    Total Current Assets Annual Cr 3,1713,205
    Total Assets Annual Cr 6,9586,609
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 7563
    ROE Annual % 1922
    ROCE Annual % 2525
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2628
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 1,2241,1821,3811,5451,5761,5391,425
    Operating Expenses Qtr Cr 1,0371,0151,0951,1411,1271,0851,028
    Operating Profit Qtr Cr 188167286404449454397
    Depreciation Qtr Cr 93918784827166
    Interest Qtr Cr 42395343402931
    Tax Qtr Cr 151240759410370
    Net Profit Qtr Cr 3725103203233251231
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 6,0474,949
    Operating Expenses Annual Cr 4,4483,513
    Operating Profit Annual in Cr 1,5921,422
    Depreciation Cr 324251
    Interest Annual Cr 165101
    Tax Annual Cr 312251
    Net Profit Annual Cr 790828
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 994911
    Cash from Investing Activity Annual Cr -996-914
    Cash from Financing Annual Activity Cr -2730
    Net Cash Flow Annual Cr -2927
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 4,0383,351
    Fixed Assets Annual Cr 3,7133,219
    Total Non Current Assets Annual Cr 4,1993,623
    Total Current Assets Annual Cr 3,4623,345
    Total Assets Annual Cr 7,6606,968
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 7563
    ROE Annual % 2025
    ROCE Annual % 2428
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2629
    Invest in Laurus Labs

    Laurus Labs Technicals

    EMA & SMA

    Current Price
    ₹380.95
    6.15 (1.64%)
    pointer
    • Bullish Moving Average
    • ___
    • 15
    • Bearish Moving Average
    • ___
    • 1
    • 20 Day
    • ₹372.49
    • 50 Day
    • ₹376.73
    • 100 Day
    • ₹374.97
    • 200 Day
    • ₹379.11
    • 20 Day
    • ₹370.01
    • 50 Day
    • ₹381.24
    • 100 Day
    • ₹379.72
    • 200 Day
    • ₹352.13

    Laurus Labs Resistance and Support

    PIVOT
    ₹374.52
    Resistance
    First Resistance 377.03
    Second Resistance 379.27
    Third Resistance 381.78
    RSI 51.11
    MFI 69.35
    MACD Single Line -2.99
    MACD -1.76
    Support
    First Resistance 372.28
    Second Resistance 369.77
    Third Resistance 367.53

    Laurus Labs Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 3,961,573 314,588,512 79.41
    Week 1,709,762 113,613,652 66.45
    1 Month 1,217,468 67,508,601 55.45
    6 Month 2,424,957 91,396,637 37.69

    Laurus Labs Result Highlights

    Laurus Labs Synopsis

    NSE-Medical-Diversified

    Laurus Labs is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company’s Total Operating Revenue is Rs. 5773.45 Cr. and Equity Capital is Rs. 107.73 Cr. for the Year ended 31/03/2023. Laurus Labs Ltd. is a Public Limited Listed company incorporated on 19/09/2005 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24239AP2005PLC047518 and registration number is 047518.
    Market Cap 20,485
    Sales 5,046
    Shares in Float 39.32
    No of funds 221
    Yield 0.43
    Book Value 4.98
    U/D Vol ratio 1.1
    LTDebt / Equity 14
    Alpha -0.05
    Beta 0.88

    Laurus Labs

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 27.2%27.2%27.2%27.2%
    Mutual Funds 5.29%5.14%5.4%5.41%
    Insurance Companies 5.41%4.99%4.15%3.92%
    Foreign Portfolio Investors 24.03%22.52%22.42%21.9%
    Financial Institutions/ Banks 0.01%0.01%
    Individual Investors 26.49%28.26%28.49%28.95%
    Others 11.57%11.88%12.34%12.62%

    Laurus Labs Management

    Name Designation
    Dr. M Venu Gopala Rao Non Exe.Chairman&Ind.Director
    Dr. C V Lakshmana Rao Executive Director
    Dr. Satyanarayana Chava Executive Director & CEO
    Mr. V V Ravi Kumar Executive Director & CFO
    Dr. Ravindranath Kancherla Independent Director
    Mrs. Aruna Rajendra Bhinge Independent Director
    Dr. Rajesh Koshy Chandy Independent Director
    Mr. Chandrakanth Chereddi Non Executive Director

    Laurus Labs Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Laurus Labs Corporate Action

    Date Purpose Remarks
    2023-10-20 Quarterly Results & Interim Dividend
    2023-07-27 Quarterly Results
    2023-04-27 Audited Results & 2nd Interim Dividend
    2023-01-30 Quarterly Results
    2022-10-21 Quarterly Results & Interim Dividend
    Date Purpose Remarks
    2023-11-02 INTERIM Rs.0.40 per share(20%)Interim Dividend
    2023-05-10 INTERIM Rs.1.20 per share(60%)Interim Dividend
    2022-11-04 INTERIM Rs.0.80 per share(40%)Interim Dividend
    2022-05-11 INTERIM Rs.1.20 per share (60%) Second Interim Dividend
    2021-11-18 INTERIM Rs.0.80 per share(40%)Interim Dividend
    Date Purpose Remarks
    2020-09-30 Split Rs.0.00 split from Rs. 10/- to Rs. 2/-.

    Laurus Labs MF Shareholding

    Name Amount(cr)
    Nippon India Small Cap Fund - Growth 37,319
    Kotak Emerging Equity Scheme Growth 33,700
    Kotak Equity Arbitrage Fund Growth 28,958
    SBI Arbitrage Opportunities Fund Regular Growth 22,370
    Axis Small Cap Fund Regular Growth 16,369

    Laurus Labs FAQs

    What is Share Price of Laurus Labs ?

    Laurus Labs share price is ₹380 As on 30 November, 2023 | 11:09

    What is the Market Cap of Laurus Labs ?

    The Market Cap of Laurus Labs is ₹20519.9 Cr As on 30 November, 2023 | 11:09

    What is the P/E ratio of Laurus Labs ?

    The P/E ratio of Laurus Labs is 55.8 As on 30 November, 2023 | 11:09

    What is the PB ratio of Laurus Labs ?

    The PB ratio of Laurus Labs is 5.1 As on 30 November, 2023 | 11:09

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.